In Korea, the number of suboptimal responders to rescue combination therapy is also
increasing. As a matter of fact, according to the investigations in Korea, HBV DNA
undetectability at 48 weeks of adefovir and lamivudine combination rescue therapy for
patients with lamivudine resistance was reported to be only 32.4%, which suggested that the
appropriate another rescue therapy might be urgently required. However, there is no promising
oral antiviral agents to control these patients in Asia-Pacific region, where tenofovir is
not widely available. Tenofovir has a higher potent antiviral efficacy and a negligible drug
resistance rate. The switch from adefovir to tenofovir in patients who have insufficient
hepatitis B virus (HBV) suppression (HBV DNA ≥ 60 IU/mL by PCR) may lead to increased viral
suppression or more HBeAg loss/seroconversion.
Here, the investigators aimed to conduct a randomized study on evaluating the antiviral
efficacy, safety, and tolerability of switching from adefovir to tenofovir in chronic
hepatitis B patients who have suboptimal response to adefovir-based combination rescue
therapy due to nucleoside analogues Resistance (SATIS study).